{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T07:12:08Z","timestamp":1785222728495,"version":"3.55.0"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"19","license":[{"start":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T00:00:00Z","timestamp":1745884800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Purpose<\/jats:title>\n                  <jats:p>Estimated glomerular filtration rate (eGFR) is the standard for categorizing renal function. Current creatinine-based estimates have been demonstrated to have limited accuracy, with national organizations encouraging use of cystatin C to calculate eGFR. This study aimed to describe the relationship between eGFR calculated using serum cystatin C (eGFRcysC) vs serum creatinine (eGFRcreat) using Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equations.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A retrospective review was performed for the period from July 2018 through June 2022 that included inpatient adults with a measured serum cystatin C level and a paired serum creatinine level obtained within 24 hours of each other. eGFRcreat and eGFRcysC were calculated using the CKD-EPI equations. The primary objective was to identify factors that were significantly associated with discordance between eGFRcysC vs eGFRcreat, which was expressed as the percentage difference in eGFR (eGFRpct_diff). Differences in eGFRpct_diff by patient subgroup were assessed using a paired t test or ANOVA as appropriate. Univariate and multivariate regression analyses were performed to further identify variables associated with eGFRpct_diff.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The study population included 226 patients. The mean (95% confidence interval) eGFRpct_diff by patient subgroup was as follows: CKD stage 4, 45.0% (25.6% to 64.4%); weight loss of greater than 10% in 1 year, \u201333.9% (\u201345.6% to \u201322.2%); cancer, \u201336.1% (\u201348.2% to \u201324.1%); and hemiplegia, \u201332.7% (\u201346.2% to \u201319.2%). Thirty-seven patients had at least one 24-hour urine collection for determination of creatinine clearance. Measured 24-hour creatinine clearance was better correlated with eGFRcysC (R2 = 0.754) than it was with eGFRcreat (R2 = 0.557) or creatinine clearance calculated using the Cockcroft-Gault creatinine equation (R2 = 0.288).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Cautious interpretation is recommended when estimating renal function from serum creatinine alone in patients with conditions associated with loss of muscle mass, including weight loss, cancer, hemiplegia, and immobility.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ajhp\/zxaf097","type":"journal-article","created":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T07:44:46Z","timestamp":1745394286000},"page":"e812-e818","source":"Crossref","is-referenced-by-count":1,"title":["Evaluation of clinical factors associated with discordant estimated glomerular filtration rate values determined from creatinine vs cystatin C"],"prefix":"10.1093","volume":"82","author":[{"given":"Shemual","family":"Tsai","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Banner University Medical Center\u2013Tucson , Tucson, AZ"},{"name":"Department of Pharmacy Practice & Science, University of Arizona R. Ken Coit College of Pharmacy , Tucson, AZ ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"April","family":"Wayne","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Banner University Medical Center\u2013Tucson , Tucson, AZ"},{"name":"Department of Pharmacy Practice & Science, University of Arizona R. Ken Coit College of Pharmacy , Tucson, AZ ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian L","family":"Erstad","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Banner University Medical Center\u2013Tucson , Tucson, AZ"},{"name":"Department of Pharmacy Practice & Science, University of Arizona R. Ken Coit College of Pharmacy , Tucson, AZ ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E","family":"Nix","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Banner University Medical Center\u2013Tucson , Tucson, AZ"},{"name":"Department of Pharmacy Practice & Science, University of Arizona R. Ken Coit College of Pharmacy , Tucson, AZ ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,4,29]]},"reference":[{"issue":"1","key":"2025092301413433300_CIT0001","first-page":"1","article-title":"KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2013","journal-title":"Kidney Int Suppl"},{"key":"2025092301413433300_CIT0002","doi-asserted-by":"crossref","first-page":"n1992","DOI":"10.1136\/bmj.n1992","article-title":"Guideline Committee. Chronic kidney disease: summary of updated NICE guidance","volume":"374","author":"Martinez","year":"2021","journal-title":"Br Med J"},{"issue":"1","key":"2025092301413433300_CIT0003","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"issue":"1","key":"2025092301413433300_CIT0004","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa1114248","article-title":"Estimating glomerular filtration rate from serum creatinine and cystatin C","volume":"367","author":"Inker","year":"2012","journal-title":"N Engl J Med"},{"issue":"19","key":"2025092301413433300_CIT0005","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New creatinine- and cystatin C-based equations to estimate GFR without race","volume":"385","author":"Inker","year":"2021","journal-title":"N Engl J Med"},{"issue":"21","key":"2025092301413433300_CIT0006","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.2146\/ajhp160467","article-title":"Should estimates of glomerular filtration rate and creatinine clearance be indexed to body surface area for drug dosing","volume":"74","author":"Nix","year":"2017","journal-title":"Am J Health-Syst Pham"},{"issue":"2","key":"2025092301413433300_CIT0007","doi-asserted-by":"crossref","first-page":"348","DOI":"10.2215\/CJN.02870707","article-title":"Influence of muscle mass and physical activity on serum and urinary creatinine and serum cystatin C","volume":"3","author":"Baxmann","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"issue":"9","key":"2025092301413433300_CIT0008","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1001\/jama.2022.12407","article-title":"Serum cystatin C for estimation of GFR","volume":"328","author":"Shlipak","year":"2022","journal-title":"JAMA"},{"issue":"2","key":"2025092301413433300_CIT0009","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1093\/ndt\/gfp474","article-title":"Age and cystatin C in healthy adults: a collaborative study","volume":"25","author":"Odden","year":"2010","journal-title":"Nephrol Dial Transplant"},{"issue":"12","key":"2025092301413433300_CIT0010","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1681\/ASN.2021070988","article-title":"A unifying approach for GFR estimation: recommendations of the NKF-ASN Task Force on reassessing the inclusion of race in diagnosing kidney disease","volume":"32","author":"Delgado","year":"2021","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"2025092301413433300_CIT0011","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1515\/CCLM.1999.064","article-title":"Serum cystatin C as an endogenous marker of the renal function\u2014a review","volume":"37","author":"Randers","year":"1999","journal-title":"Clin Chem Lab Med"},{"issue":"1","key":"2025092301413433300_CIT0012","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clinbiochem.2004.09.025","article-title":"Cystatin C as a marker of GFR\u2014history, indications, and future research","volume":"38","author":"Filler","year":"2005","journal-title":"Clin Biochem"},{"issue":"5","key":"2025092301413433300_CIT0013","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1093\/clinchem\/48.5.699","article-title":"Cystatin C: an improved estimator of glomerular filtration rate","volume":"48","author":"Laterza","year":"2002","journal-title":"Clin Chem"},{"issue":"1","key":"2025092301413433300_CIT0014","doi-asserted-by":"crossref","first-page":"e0226509","DOI":"10.1371\/journal.pone.0226509","article-title":"Creatinine versus cystatin C for renal function-based mortality prediction in an elderly cohort: the Northern Manhattan Study","volume":"15","author":"Willey","year":"2020","journal-title":"PLoS One"},{"issue":"5","key":"2025092301413433300_CIT0015","first-page":"303","article-title":"A formula to estimate the approximate surface area if height and weight be known. 1916","volume":"5","author":"Du Bois","year":"1989","journal-title":"Nutrition"},{"issue":"5","key":"2025092301413433300_CIT0016","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1053\/j.ajkd.2023.04.002","article-title":"Discordances between creatinine- and cystatin C-based estimated GFR and adverse clinical outcomes in routine clinical practice","volume":"82","author":"Carrero","year":"2023","journal-title":"Am J Kidney Dis"},{"issue":"7","key":"2025092301413433300_CIT0017","doi-asserted-by":"crossref","first-page":"e2321715","DOI":"10.1001\/jamanetworkopen.2023.21715","article-title":"Medication-related adverse events and discordancies in cystatin C-based vs serum creatinine-based estimated glomerular filtration rate in patients with cancer","volume":"6","author":"Hanna","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"1","key":"2025092301413433300_CIT0018","doi-asserted-by":"crossref","first-page":"57","DOI":"10.5527\/wjn.v4.i1.57","article-title":"Biomarkers in chronic kidney disease, from kidney function to kidney damage","volume":"4","author":"Lopez-Giacoman","year":"2015","journal-title":"World J Nephrol"},{"issue":"6","key":"2025092301413433300_CIT0019","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1038\/ki.2008.638","article-title":"Factors other than glomerular filtration rate affect serum cystatin C levels","volume":"75","author":"Stevens","year":"2009","journal-title":"Kidney Int"},{"issue":"10","key":"2025092301413433300_CIT0020","doi-asserted-by":"crossref","first-page":"e2238300","DOI":"10.1001\/jamanetworkopen.2022.38300","article-title":"Assessment of cystatin C level for risk stratification in adults with chronic kidney disease","volume":"5","author":"Lees","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"1","key":"2025092301413433300_CIT0021","doi-asserted-by":"crossref","first-page":"e0206839","DOI":"10.1371\/journal.pone.0206839","article-title":"Creatinine- versus cystatin C-based renal function assessment in the Northern Manhattan Study","volume":"13","author":"Husain","year":"2018","journal-title":"PLoS One"},{"issue":"5","key":"2025092301413433300_CIT0022","doi-asserted-by":"crossref","first-page":"217","DOI":"10.5414\/CN109573","article-title":"Comparison of cystatin C and creatinine-based estimated glomerular filtration rate equations among elderly chronic kidney disease patients attending a tertiary care hospital: a prospective cross-sectional study","volume":"93","author":"Khan","year":"2020","journal-title":"Clin Nephrol"},{"issue":"4","key":"2025092301413433300_CIT0023","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1136\/heartjnl-2020-318860","article-title":"Addition of cystatin C predicts cardiovascular death better than creatinine in intensive care","volume":"108","author":"Helmersson-Karlqvist","year":"2022","journal-title":"Heart"},{"key":"2025092301413433300_CIT0024","first-page":"9349280","article-title":"Cystatin C falsely underestimated GFR in a critically ill patient with a new diagnosis of AIDS","author":"Brown","year":"2016","journal-title":"Case Rep Nephrol"},{"issue":"1-2","key":"2025092301413433300_CIT0025","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0009-8981(00)00234-5","article-title":"Clinical value of cystatin C determination","volume":"297","author":"Page","year":"2000","journal-title":"Clin Chim Acta"},{"issue":"4","key":"2025092301413433300_CIT0026","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1111\/j.1523-1755.2004.00517.x","article-title":"Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement","volume":"65","author":"Knight","year":"2004","journal-title":"Kidney Int"},{"key":"2025092301413433300_CIT0027","doi-asserted-by":"crossref","first-page":"899658","DOI":"10.3389\/fneur.2022.899658","article-title":"Prevalence and risk factors of stroke-related sarcopenia at the subacute stage: a case control study","volume":"13","author":"Yao","year":"2022","journal-title":"Front Neurol"},{"key":"2025092301413433300_CIT0028","doi-asserted-by":"crossref","first-page":"111561","DOI":"10.1016\/j.exger.2021.111561","article-title":"Aging, obesity, sarcopenia and the effect of diet and exercise intervention","volume":"155","author":"Colleluori","year":"2021","journal-title":"Exp Gerontol"},{"issue":"12","key":"2025092301413433300_CIT0029","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.trecan.2018.10.001","article-title":"Cancer cachexia: more than skeletal muscle wasting","volume":"4","author":"Schmidt","year":"2018","journal-title":"Trends Cancer"},{"issue":"2","key":"2025092301413433300_CIT0030","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/nrclinonc.2012.209","article-title":"Understanding the mechanisms and treatment options in cancer cachexia","volume":"10","author":"Fearon","year":"2013","journal-title":"Nat Rev Clin Oncol"},{"issue":"7","key":"2025092301413433300_CIT0031","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.2337\/dc09-2310","article-title":"Prevalence and determinant factors of sarcopenia in patients with type 2 diabetes: the Korean Sarcopenic Obesity Study (KSOS)","volume":"33","author":"Kim","year":"2010","journal-title":"Diabetes Care"},{"key":"2025092301413433300_CIT0032","doi-asserted-by":"crossref","first-page":"38937","DOI":"10.1038\/srep38937","article-title":"Type 2 diabetes mellitus is associated with increased risks of sarcopenia and pre-sarcopenia in Chinese elderly","volume":"6","author":"Wang","year":"2016","journal-title":"Sci Rep"},{"issue":"2","key":"2025092301413433300_CIT0033","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1177\/0884533613520619","article-title":"Sarcopenia in solid organ transplantation","volume":"29","author":"Carey","year":"2014","journal-title":"Nutr Clin Pract"},{"issue":"6","key":"2025092301413433300_CIT0034","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1053\/j.ajkd.2020.11.032","article-title":"Changes in body composition, muscle strength, and fat distribution following kidney transplantation","volume":"78","author":"Dienemann","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"2025092301413433300_CIT0035","doi-asserted-by":"crossref","first-page":"923","DOI":"10.2147\/CLEP.S218697","article-title":"Charlson Comorbidity Index based on hospital episode statistics performs adequately in predicting mortality, but its discriminative ability diminishes over time","volume":"11","author":"Pylv\u00e4l\u00e4inen","year":"2019","journal-title":"Clin Epidemiol"},{"issue":"1","key":"2025092301413433300_CIT0036","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1631\/jzus.B1300109","article-title":"Charlson Comorbidity Index helps predict the risk of mortality for patients with type 2 diabetic nephropathy","volume":"15","author":"Huang","year":"2014","journal-title":"J Zhejiang Univ Sci B"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxaf097\/63024760\/zxaf097.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/82\/19\/e812\/63024760\/zxaf097.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/82\/19\/e812\/63024760\/zxaf097.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T05:41:45Z","timestamp":1758606105000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/82\/19\/e812\/8121432"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,29]]},"references-count":36,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2025,4,29]]},"published-print":{"date-parts":[[2025,9,23]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxaf097","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10,1]]},"published":{"date-parts":[[2025,4,29]]}}}